Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer's disease.

Cell Mol Life Sci · 2022 · PMC8979934 · PMID 35377002

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

PK pre-treatment showed a trend in reducing AβO and TauO binding to human FC and HP synaptosomes, especially at the 2.5 μM and 5 μM concentrations of both oligomers (Supplementary Fig. 6, Additional file 1).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.